First disease-modifying therapy approved for pediatric multiple sclerosis: industry news round-up

Written by Sharon Salt, Editor

This week’s industry news round-up reveals the latest updates including neuroblastoma, DUB inhibitors for neurodegenerative disorders and the first disease-modifying therapy for pediatric multiple sclerosis. Find out more about our selection of the highlights below. Our pick of the highlights include: NICE issues draft guidance against EUSA Pharma’s neuroblastoma drug Qarziba® Multi-year collaboration to develop DUB inhibitors for the treatment of neurodegenerative diseases First disease-modifying therapy approved for pediatric multiple sclerosis NICE issues draft guidance against EUSA Pharma’s neuroblastoma drug Qarziba® NICE has issued a draft guidance recommending against EUSA Pharma’s Qarziba® (dinutuximab beta; Hemel Hemsptead, UK) as a treatment...

To view the full article, please register now for access

It's completely free